

Pressmeddelande
Xintela AB (publ)
556780-3480
2020-10-30



Status report of Xintela published

Lund, Sweden, 30 October 2020 - Xintela announces that a status report of the company has been published by Biostock, that contains both Biostock's own analysis and information provided by Xintela.

Read the analysis through the below link.

<https://www.biostock.se/en/status-report-xintela-integrins-marking-the-future/>

Xintela AB (publ)

Evvy Lundgren-Åkerlund, CEO

Tel: +46 46 275 65 00

Email: evvy@xintela.se

Medicon Village

223 81 Lund, Sweden

www.xintela.se

About Xintela

Xintela is an Advanced Therapy company developing regenerative cell therapies and targeted cancer therapies based on the patented marker technology platform XINMARK®. The platform is built on specific cell surface proteins (integrins) and more than 25 years of research and development. Xintela uses the marker technology to isolate and quality assure stem cells for the treatment of musculoskeletal diseases including osteoarthritis (OA). Studies on horses with OA have demonstrated that the stem cells are safe and that they have a positive effect on cartilage and bone. Xintela has established an in-house GMP-facility for manufacturing of stem cells and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma and triple-negative breast cancer. Xintela is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.